Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
Business
·
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
CN
CitrixNews Staff
Originally reported by New York Times. Read the full story at the original source.
Related Articles
Business
Travelodge failed sex assault victim 'at every stage'
Image caption, The review found Travelodge guests were still not as safe as they should bePublished1 October 2026, 11:17...
CitrixNews Staff
·
57 minutes ago
Business
Pension tops £16,000 a year after 4.7% increase
Image source, PA MediaImage caption, The 4.7% increase will bring the overall pension sum to £16,294 per yearPublished51...
CitrixNews Staff
·
1 hour ago
Business
How Middle East Oil Exports Started Recovering
Our business reporter Peter Eavis describes how oil exports from the Middle East have rebounded this month, getting clos...
CitrixNews Staff
·
2 hours ago
Business
When Data Centers Cluster Together, How Dirty Are They? One County Wants Answers.
An unusual study aims to estimate the pollution and health costs from a cluster of proposed data centers, instead of con...
CitrixNews Staff
·
2 hours ago